Breaking

BofA's Countrywide Is Ordered to Pay $1.3B for Defective Loans
Tweet TWEET

Pain Pill Makers Get Guidance on Thwarting Drug Addicts

Companies making opioid painkillers were given a better idea by the U.S. government today of how to prove their pills are resistant to abuse by recreational users.

The Food and Drug Administration proposed a guideline outlining studies drugmakers should conduct to demonstrate abuse deterrence. The guidance also makes clear to companies what claims abuse-resistant painkillers can make on the ability to block the effect of an opioid when manipulated, such as when the pills are crushed and snorted for a more intense effect.

The FDA isn’t requiring abuse-resistant painkillers, rather it wants to determine what strategies work best, Douglas Throckmorton, deputy director at the agency’s office that oversees drug reviews, said on a conference call with reporters. Regulators plan to be flexible as companies adopt the technology.

“This draft guidance is an important part of a larger effort by FDA aimed at preventing prescription drug abuse and misuse,” Commissioner Margaret Hamburg said in a statement, calling opioid addiction a major public health challenge.

FDA advisers decided Dec. 7 against recommending Zogenix Inc. (ZGNX)’s single-ingredient hydrocodone painkiller Zohydro for approval after they determined it needed more protections from abuse. Zogenix is working on an abuse-deterrent formulation that hasn’t been submitted to the FDA for approval.

Label Claims

Endo Health Solutions Inc. (ENDP) already makes an extended- release oxymorphone called Opana that is tamper resistant. The Chadds Ford, Pennsylvania-based company took its earlier version of Opana without the abuse deterrent off the market.

Endo can’t claim the product is abuse-resistant on the label. The FDA hasn’t approved any labeling that claims an opioid can reduce abuse, Throckmorton said.

Purdue Pharma, based in Stamford, Connecticut, is working on an abuse-resistant formulation of pure hydrocodone, the company said last month in a statement.

The FDA is asking for public comment on the guideline for 60 days and plans to hold a public meeting, which hasn’t yet been scheduled.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.